Don't miss a digital issue! Renew/subscribe for FREE today.
 Advertisement ×

Sevāredent Sourcing Solutions and Pacira BioSciences Collaborate to Provide Expanded Access to EXPAREL for Patients Undergoing Oral and Maxillofacial Procedures

Posted on Wednesday, September 28, 2022

The agreement will facilitate easier access to long-acting non-opioid pain control in over 1,800 member offices

Sevāredent Sourcing Solutions, a Group Purchasing Organization (GPO) that creates a competitive advantage for like-minded dental organizations through best-in-class vendor partnerships that drive supply chain value and efficiency, and Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced a joint initiative to provide expanded access to EXPAREL® (bupivacaine liposome injectable suspension) for patients undergoing oral and maxillofacial (OMFS) procedures ranging from third molar and full mouth extractions to dentures and implants.

This collaboration, which advances Sevāredent’s goal of improving patient outcomes and reducing exposure to opioids and their associated risks, provides easy access to EXPAREL—including comprehensive product training and onboarding support from Pacira—for more than 1,800 dental offices across the United States.

“The patient experience, and particularly the recovery process, is paramount for individuals undergoing oral surgery procedures. Many patients express concerns about both postsurgical pain and opioid exposure,” said Blake Hibray, Sevāredent President. “By partnering with Pacira to offer a long-acting local analgesic like EXPAREL to our vast network of dentists and oral surgeons, we believe we can make a meaningful difference in the lives of patients undergoing oral and maxillofacial procedures by effectively managing their pain and simultaneously decreasing their risk of opioid exposure during the recovery period.”

EXPAREL has been studied across a wide variety of oral and maxillofacial procedures including full arch implant, third molar extraction and soft palate surgeries.

“The Sevāredent partnership is another important step toward advancing our commitment to provide a non-opioid pain management option to as many patients as possible,” said Dave Stack, Chief Executive Officer and Chairman of Pacira BioSciences, Inc. “Given the national awareness on the burgeoning opioid crisis, dental patients and their caregivers—often their parents in the case of wisdom tooth extraction patients—are increasingly motivated to seek out providers who offer a non-opioid alternative like EXPAREL that can reduce or eliminate opioid exposure while providing prolonged pain control for several days. We are thrilled to partner with Sevāredent to increase access to providers and patients alike.”


© 2022 BroadcastMed LLC | Privacy Policy